SEC Form 4 · accession 0001683168-18-002939
International Stem Cell CORP · ISCO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Sophia Garnette
Officer — VP, Legal Affairs & Operation
Period of report
Oct 2, 2018
Accepted (ET)
Oct 3, 2018 · 4:45 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001355790
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Oct 2, 2018 | M | 1,494 | $1.10 | A | 1,761 | D | |
| Common StockF1 | Oct 2, 2018 | S | 1,494 | $1.58 | D | 267 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $1.10 | Oct 2, 2018 | M | 1,494 | D | — | May 31, 2027 | Common Stock | 49,352 | 47,858 | D |
Explanation of responses
- F1The reported shares were sold in open market transactions through a broker-dealer at $1.58 per share.
- F2The option, representing a total of 60,000 shares, became exercisable "vested" in installments. 3/36th of the shares underlying such options vested on August 31, 2017, and the remaining shares in equal monthly installments over a period of 33 months.